The demise of this company was the purchase of Synageva and the bloated price they paid. They never recovered. Also the failed sales projections on their drugs.
They've been incorrect on all profit projections and their company value has been cut in half.
That being said, the stock price should be too. This stock price should be more in line with $60.00 per share.
Look at their layoffs. They are dumping people left and right. They received a huge tax break from the governor for staying in Connecticut if they create jobs, but that's not happening.
And you'll see more layoffs to come. I'd like to know how they're not reneging on the governor's agreement of creating more jobs.
You must own stock in this and now underwater.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM